One special question to start with: Can HIF/NFkB be a target in inflammation?

Endocrine, Metabolic and Immune Disorders - Drug Targets

Volumn 15, Issue 3, 2015, Pages 171-185

  Russo, Matteo A ^a   Sansone, Luigi ^a   Carnevale, Ilaria ^a,b   Limana, Federica ^a   Runci, Alessandra ^a,b   Polletta, Lucia ^b   Perrone, Giulietta A ^c   De Santis, Elena ^b   Tafani, Marco ^a,b  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c SAN FILIPPO NERI HOSPITAL   (Italy)

Author keywords

Hypoxia; Inflammation; Molecular rehabilitation; Stress response; Tissue and cell repair

Indexed keywords

2 METHOXYESTRADIOL; ADVANCED GLYCATION END PRODUCT RECEPTOR; AMINOGUANIDINE; BORTEZOMIB; CURCUMIN; CYTARABINE; DIGOXIN; HISTONE DEACETYLASE; HYPOXIA INDUCIBLE FACTOR; INFLAMMASOME; INTERLEUKIN 1BETA CONVERTING ENZYME; LYSOZYME; METFORMIN; NUCLEAR FACTOR; PARTHENOLIDE; PYRIDOXAMINE; RAPAMYCIN; REACTIVE OXYGEN METABOLITE; RESVERATROL; SIRTUIN; VASCULOTROPIN; ANTIINFLAMMATORY AGENT; AUTACOID; HYPOXIA INDUCIBLE FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ADAPTIVE IMMUNITY; AGING; ARTERY OCCLUSION; ARTICLE; AUTOIMMUNE DISEASE; CARCINOGENESIS; CELL DEATH; CELL REGENERATION; CYTOKINE STORM; DEGENERATIVE DISEASE; DIABETES MELLITUS; DISEASE COURSE; GENE EXPRESSION; GENE MUTATION; HUMAN; HYPERTROPHY; HYPOXIA; INFARCTION; INFLAMMATION; INFLAMMATORY DISEASE; INNATE IMMUNITY; LEUKOCYTE; OBESITY; THROMBOSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG DELIVERY SYSTEM; METABOLISM; PROCEDURES;

ANIMALS; ANTI-INFLAMMATORY AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; INFLAMMATION; INFLAMMATION MEDIATORS; NF-KAPPA B;

EID: 84942117217     PISSN: 18715303     EISSN: 22123873     Source Type: Journal    
DOI: 10.2174/1871530315666150316120112     Document Type: Article

References (150)

1. Eltzschig, H.K.; Carmeliet, P. Hypoxia and inflammation. N. Engl. J. Med., 2011, 364, 656-665.
2. Schanne, F.A.; Kane, A.B.; Young, E.E.; Farber, J.L. Calcium dependence of toxic cell death: a final common pathway. Science, 1979, 206, 700-702.
3. Russo, M.A.; Cittadini, A.; Dani, A.M.; Inesi, G.; Terranova, T. An ultrastructural study of calcium induced degenerative changes in dissociated heart cells. J. Mol. Cell. Cardiol., 1981, 13, 265-279.
4. Russo, M.A.; Kane, A.B.; Farber, J.L. Ultrastruct pathology of phalloidin-intoxicated hepatocytes in the presence and absence of extracellular calcium. Am. J. Pathol., 1982, 109, 133-144.
5. Smith, M.A.; Schnellmann, R.G. Calpains, mitochondria, and apoptosis. Cardiovasc. Res., 2012, 96, 32-37.
6. Nagamalleswari, E.; Vasu, K.; Nagaraja, V. Ca(2+) binding to the ExDxD motif regulates the DNA cleavage specificity of a promiscuous endonuclease. Biochemistry, 2012, 51, 8939-8949.
7. Semenza, G.L. Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology. Annu. Rev. Pathol., 2014, 9, 47-71.
8. Tafani, M.; Schito, L.; Pellegrini, L.; Villanova, L.; Marfe, G.; Anwar, T.; Rosa, R.; Indelicato, M.; Fini, M.; Pucci, B.; Russo, M.A. Hypoxia-increased RAGE and P2X7R expression regulates tumor cell invasion through phosphorylation of Erk1/2 and Akt and nuclear translocation of NF-{kappa}B. Carcinogenesis, 2011, 32, 1167-75.
9. Sandholm, J.; Tuomela, J.; Kauppila, J.H.; Harris, K.W.; Graves, D. and Selander, K.S. Hypoxia regulates Toll-like receptor-9 expression and invasive function in human brain cancer cells in vitro. OncolLett., 2014, 8, 266-274.
10. Jones, H.D.; Crother, T.R.; Gonzalez-Villalobos, R.A.; Jupelli, M.; Chen, S.; Dagvadorj, J.; Arditi, M.; Shimada, K. The NLRP3 inflammasome is required for the development of hypoxemia in LPS/mechanical ventilation acute lung injury. Am. J. Respir. Cell. Mol. Biol., 2014, 50, 270-280.
11. Tafani, M.; Perrone, G.A.; Pucci, B.; Russo, A.; Bizzarri, M.; Mechanick, J.I.; Carpi, A. and Russo, M.A. Reprogramming cancer cells in endocrine-related tumors: open issues. Curr. Med. Chem., 2014, 21, 1146-51.
12. Strowig, T.; Henao-Mejia, J.; Elinav, E.; Flavell, R. Inflammasomes in health and disease. Nature, 2012, 481, 278-86.
13. Bianchi, M.E. DAMPs, PAMPs and alarmins: all we need to know about danger. J. Leukoc. Biol., 2007, 81, 1-5.
14. Iwasaki, A.; Medzhitov, R. Toll-like receptors control of the adaptative immunity response. Nat. Immunol., 2004, 5, 987-995.
15. Marshak-Rothstein, A. Toll-like receptors in systemic autoimmune disease Nat. Rev. Immunol., 2006, 6, 823-835.
16. Fritz, J.H.; Ferrero, R.L.; Philpott, D.J.; Girardin, S.E. NOD-like proteins in immunity, inflammation and diseases Nature Immunol., 2006, 7, 1250-1257.
17. Yazdi, A.S.; Guarda, G.; Riteau, N.; Drexler, S.K.; Tardivel, A.; Couillin, I.; Tschopp, J. Nanoparticles activate the NLR pyrin domain containing 3 (Nlrp3) inflammasome and cause pulmonary inflammation through release of IL-1α and IL-1β. Proc Natl Acad Sci U S A., 2010, 107, 19449-19454.
18. Hillegass, J.M.; Miller, J.M.; MacPherson, M.B.; Westbom, C.M.; Sayan, M.; Thompson, J.K.; Macura, S.L.; Perkins, T.N.; Beuschel, S.L.; Alexeeva, V.; Pass, H.I.; Steele, C.; Mossman, B.T.; Shukla, A. Asbestos and erionite prime and activate the NLRP3 inflammasome that stimulates autocrine cytokine release in human mesothelial cells. Part. Fibre Toxicol., 2013, 10, 39.
19. Robbins, G.R.; Wen, H.; Ting, J.P. () Inflammasomes and metabolic disorders: old genes in modern diseases. Mol. Cell., 2014, 54, 297-308.
20. Kono, H; Rock, K.L. How dying cells alert the immune system to danger. Nat. Rev. Immunol., 2008, 8, 279-289
21. Burnstock, G.; Di Virgilio, F. Purinergic signalling and cancer. Purin Signal, 2013, 9, 491-540.
22. Huynh, M.L.; Fadok, V.A.; Henson, P.M. Phosphatidylserinedependent ingestion of apoptotic cells promotes TGF-β1 secretion and the resolution of inflammation. J. Clin. Invest., 2002, 109, 41-50.
23. Grivennikov, S.I.; Greten, F.R.; Karin, M. Immunity, inflammation, and cancer. Cell, 2010, 140, 883-899.
24. Tafani, M.; Di Vito, M.; Frati, A.; Pellegrini, L.; De Santis, E.; Sette, G.; Eramo, A.; Sale, P.; Mari, E.; Santoro, A.; Raco, A.; Salvati, M.; De Maria, R.; Russo, M.A. Pro-inflammatory gene expression in solid glioblastoma microenvironment and in hypoxic stem cells from human glioblastoma. J. Neuroinflammation, 2011, 8, 32.
25. Ryan, B.J.; Nissim, A.; Winyard, P.G. Oxidative post-translational modifications and their involvement in the pathogenesis of autoimmune diseases. Redox. Biol., 2014, 2, 715-724.
26. Reuter, S.; Gupta, S.C.; Chaturvedi, M.M.; Aggarwal, B.B. Oxidative stress, inflammation, and cancer: how are they linked? Free RadicBiol. Med., 2010, 49, 1603-1616.
27. Martinon, F.; Burns, K.; Tschopp, J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of pro IL-beta. Mol. Cell., 2002, 10, 417-426.
28. Tabas, I.; Glass, C.K. Anti-inflammatory therapy in chronic disease: challenges and opportunities. Science, 2013, 339, 166-172.
29. Rastrick, J.; Birrell, M. The role of the inflammasome in fibrotic respiratory diseases. Minerva. Med., 2014, 105, 9-23.
30. Walsh, J.G.; Muruve, D.A.; Power, C. Inflammasomes in the CNS. Nat. Rev. Neurosci., 2014, 15, 84-97.
31. D'Elia, R.V.; Harrison, K.; Oyston, P.C.; Lukaszewski, R.A.; Clark, G.C. Targeting the "cytokine storm" for therapeutic benefit. Clin. Vaccine Immunol., 2013, 20, 319-327.
32. Mangge, H.; Becker, K.; Fuchs, D.; Gostner, J.M. Antioxidants, inflammation and cardiovascular disease. World J. Cardiol., 2014, 6, 462-477.
33. Asghar, M.N.; Emani, R.; Alam, C.; Helenius, T.O.; Gronroos, T.J.; Sareila, O.; Din, MU.; Holmdahl, R.; Hanninen, A. and Toivola, D.M. In vivo imaging of reactive oxygen and nitrogen species in murine colitis. Inflamm. Bowel. Dis., 2014, 20, 1435-1447.
34. Vallabhapurapu, S.; Karin, M. Regulation and function of NFkappaB transcription factors in the immune system. Annu. Rev. Immunol., 2009, 27, 693-733
35. Napetschnig, J.; Wu, H. Molecular basis of NF-κB signaling. Annu Rev Biophys, 2013, 42, 443-468.
36. Tafani, M.; Pucci, B.; Russo, A.; Schito, L.; Pellegrini, L.; Perrone, G.A.; Villanova, L.; Salvatori, L.; Ravenna, L.; Petrangeli, E.; Russo, M.A. Modulators of HIF1α and NFkB in Cancer Treatment: Is it a Rational Approach for Controlling Malignant Progression? Front. Pharmacol., 2013, 4, 13.
37. Ahmed, T.J., Kaneva, M.K., Pitzalis, C., Cooper, D.; Perretti, M. Resolution of inflammation: examples of peptidergic players and pathways. Drug Discov. Today, 2014, 19(8), 1166-1171.
38. Pruessmeyer, J.; Hess, F.M.; Alert, H.; Groth, E.; Pasqualon, T.; Schwarz, N.; Nyamoya, S.; Kollert, J.; van der Vorst, E.; Donners, M.; Martin, C.; Uhlig, S.; Saftig, P.; Dreymueller, D.; Ludwig, A. Leukocytes require ADAM10 but not ADAM17 for their migration and inflammatory recruitment into the alveolar space. Blood, 2014, 123, 4077-4088.
39. De Girolamo, L.; Stanco, D.; Salvatori, L.; Coroniti, G.; Arrigoni, E.; Silecchia, G.; Russo, M.A.; Niada, S.; Petrangeli, E.; Brini, A.T. Stemness and osteogenic and adipogenic potential are differently impaired in subcutaneous and visceral adipose derived stem cells (ASCs) isolated from obese donors. Int. J. Immunopathol. Pharmacol., 2013, 26, 11-21.
40. Fer, N.; Melillo, G. The HIF1α-cMyc pathway and tumorigenesis: evading the apoptotic gatekeeper. Cell Cycle, 2011, 10, 3228.
41. Zhu, P.; Ning, Y.; Yao, L; Chen, M.; Xu, C. The proliferation, apoptosis, invasion of endothelial-like epithelial ovarian cancer cells induced by hypoxia. J. Exp. Clin. Cancer Res., 2010, 29, 124.
42. Franovic, A.; Holterman, C.E.; Payette, J.; Lee, S. Human cancers converge at the HIF-2 oncogenic axis. Proc. Natl. Acad. Sci. USA, 2009, 106, 21306-21311.
43. Schito, L.; Rey, S.; Tafani, M.; Zhang, H.; Wong, C.C.; Russo, A.; Russo, M.A. and Semenza, G.L. Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells. Proc. Natl. Acad. Sci. USA, 2012, 109, E2707-16.
44. Ravenna, L.; Sale, P.; Di Vito, M.; Russo, A.; Salvatori, L.; Tafani, M.; Mari, E.; Sentinelli, S.; Petrangeli, E.; Gallucci, M.; Di Silverio, F.; Russo, M.A. Up-regulation of the inflammatory reparative phenotype in human prostate carcinoma. Prostate, 2009, 69, 1245-55.
45. Tafani, M.; Schito, L.; Pellegrini, L.; Villanova, L.; Marfe, G.; Anwar, T.; Rosa, R.; Indelicato, M.; Fini, M.; Pucci, B.; Russo, M.A. Hypoxia-increased RAGE and P2X7R expression regulates tumor cell invasion through phosphorylation of Erk1/2 and Akt and nuclear translocation of NF-{kappa}B. Carcinogenesis, 2011, 32, 1167-75.
46. Tafani, M.; Russo, A.; Di Vito, M.; Sale, P.; Pellegrini, L.; Schito, L.; Gentileschi, S.; Bracaglia, R.; Marandino, F.; Garaci, E.; Russo, M.A. Up-regulation of pro-inflammatory genes as adaptation to hypoxia in MCF-7 cells and in human mammary invasive carcinoma microenvironment. Cancer Sci., 2010, 101, 1014-23.
47. Desgrosellier, J.S.; Cheresh, D.A. Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer., 2010, 10, 9-22.
48. Richmond, A. NF-κB, chemokine gene transcription and tumour growth. Nat. Rev. Immunol., 2002, 2, 664-674
49. Balkwill, F. Cancer and chemokine network. Nat. Rev. Cancer, 2004, 4, 540-550.
50. Hussain, T.; Gupta, S.; Mukhtar, H. Cyclooxygenase-2 and prostate carcinogenesis. Cancer Lett., 2003, 191, 125-135.
51. Hussain, S.P.; He, P.; Subleski, J.; Hofseth, L.J.; Trivers, G.E.; Mechanic, L.; Hofseth, A.B.; Bernard, M.; Schwank, J.; Nguyen, G.; Mathe, E.; Djurickovic, D.; Haines, D.; Weiss, J.; Back, T.; Gruys, E.; Laubach, V.E., Wiltrout, R.H.; Harris, C.C. Nitric oxide is a key component in inflammation-accelerated tumorigenesis. Cancer Res., 2008, 68, 7130-6.
52. Wang, J.; Torbenson, M.; Wang, Q.; Ro, J.Y.; Becich, M. Expression of inducible nitric oxide synthase in paired neoplastic and non neoplastic primary prostate cell cultures and prostatectomy specimens. Urol. Oncol., 2003, 21, 117-122.
53. Rocconi, R.P.; Kirby, T.O.; Seitz, R.S.; Beck, R.; Straughn, J.M.; Alvarez, R.D.; Huh, W.K. Lipoxygenase pathway receptor expression in ovarian cancer. Reprod. Sci., 2008, 15, 321-326.
54. Lippitz, B.E. Cytokine patterns in patient with cancer: a systematic review. Lancet, 2013, 14, e218-e228
55. Strieter, R.M. Masters of angiogenesis. Nat Med, 2005, 11, 925-927.
56. Ezashi, T.; Das, P.; Roberts, R.M. Low O2 tension and prevention of differentiated hES cells. Proc. Natl. Acad. Sci. USA, 2005, 102, 4783-88.
57. Di Lorenzo, G.; Tortora, G.; D'Armiento, F.P.; De Rosa, G.; Staibano, S.; Autorino, R.; D'Armiento, M.; De Laurentiis, M.; De Placido, S.; Catalano, G.; Bianco, A.R.; Ciardiello, F. Expression of epidermal growth factor receptor correlates with disease relapse andprogression to androgen-independence in human prostatecancer. Clin. Cancer Res., 2002, 8, 3438-3444.
58. Hiratsuka, S.; Watanabe, A.; Sakurai, Y.; Akashi-Takamura, S.; Ishibashi, S.; Kiyake, K.; Shibuya, M.; Akira, S.; Aburatani, H. and Maru, Y. The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic cascade. Nat. Cell. Biol, 2008, 10, 1349-55.
59. Gabay, C.; Kushner, I. Acute-phase proteins and other systemic responses to inflammation. NEJM, 1999, 340, 448-454.
60. Deban, L.; Bottazzi, B.; Garlanda, C.; de la Torre, Y.M.; Mantovani, A. Pentraxins: multifunctional proteins at the interface of innate immunity and inflammation. Biofactors, 2009, 35, 138-45.
61. Tafani, M.; De Santis, E.; Coppola, L.; Perrone, G.A.; Carnevale, I.; Russo, A.; Pucci, B.; Carpi, A.; Bizzarri, M.; Russo, M.A. Bridging hypoxia, inflammation and estrogen receptors in thyroid cancer progression. Biomed Pharmacother, 2014, 68, 1-5.
62. De Santis, E.; Di Vito, M.; Perrone, G.A.; Mari, E.; Osti, M.; De Antoni, E.; Coppola, L.; Tafani, M.; Carpi, A.; Russo, M.A. Overexpression of pro-inflammatory genes and down-regulation of SOCS-1 in human PTC and in hypoxic BCPAP cells. Biomed. Pharmacother., 2013, 67, 7-16.
63. Anzai, T. Post-infarction inflammation and left ventricular remodeling: a double-edged sword. Circ J., 2013, 77, 580-7.
64. Volz, H.C.; Kaya, Z.; Katus, H.A.; Andrassy, M. The role of HMGB1/RAGE in inflammatory cardiomyopathy. Semin Thromb Hemost., 2010, 36, 185-194.
65. Frangogiannis, N.G.; Smith, C.W.; Entman, M.L. The inflammatory response in myocardial infarction. Cardiovasc Res., 2010, 53, 31-47.
66. Brea, D.; Sobrino, T.; Ramos-Cabrer, P.; Castillo, J. () Inflammatory and neuroimmunomodulatory changes in acute cerebral ischemia. Cerebrovasc. Dis., 2009, 27(Suppl 1), 48-64.
67. Iadecola, C.; Anrather, J. The immunology of stroke: from mechanisms to translation Nat. Med., 2011, 17, 796-808.
68. Courties, G.; Moskowitz, M.A.; Nahrendorf, M. The innate immune system after ischemic injury: lessons to be learned from the heart and brain. JAMA Neurol., 2014, 71, 233-236.
69. Becker, K. Autoimmune responses to brain following stroke. Transl Stroke Res., 2012, 3, 310-317.
70. Ye, J. Adipose tissue vascularization: its role in chronic inflammation. Curr. Diab. Rep., 2011, 11, 203-210.
71. He, Q.; Gao, Z.; Yin, J.; Zhang, J.; Yun, Z.; Ye, J. Regulation of HIF-1{alpha} activity in adipose tissue by obesity-associated factors: adipogenesis, insulin, and hypoxia. Am. J. Physiol. Endocrinol. Metab., 2011, 300, E877-E885.
72. Ye, J. Emerging role of adipose tissue hypoxia in obesity and insulin resistance. Int. J. Obes. (Lond.), 2009, 33, 54-66.
73. Caspar-Bauguil, S.; Cousin, B.; Bour, S.; Casteilla, L.; Penicaud, L.; Carpene, C. Adipose tissue lymphocytes: types and roles. J Physiol Biochem, 2009, 65, 423-436.
74. Odegaard, J.I.; Chawla, A. Pleiotropic actions of insulin resistance and inflammation in metabolic homeostasis. Science, 2013, 339, 172-177.
75. Miyata, T.; de Strihou, C.v. Diabetic nephropathy: a disorder of oxygen metabolism? Nat. Rev. Nephrol., 2010, 6, 83-95.
76. Singh, V.P.; Bali, A.; Singh, N.; Jaggi, A.S. Advanced glycation end products and diabetic complications. Korean J. PhysiolPharmacol., 2014, 18, 1-14.
77. Gugliucci, A.; Menini, T. The Axis AGE-RAGE-Soluble RAGE and Oxidative Stress in Chronic Kidney Disease. Adv. Exp. Med. Biol., 2014, 824, 191-208.
78. Winne, J.; Braunwald, E. Cardiomyopathies and myocarditis In "Harrison's Principles of Internal Medicine". 2008, Chpt 231, 1481-1488 Fauci A et al Edts, McGraw-Hill, NY.
79. Frey, N.; Olson, E.N. Cardiac Hypertrophy: The Good, the Bad, and the Ugly Annu. Rev. Physiol., 2003, 65, 45-79.
80. Frustaci, A., Russo, M.A.; Chimenti, C. Diagnostic contribution of left ventricular endomyocardial biopsy in patients with clinical phenotype of hypertrophic cardiomyopathy. Hum. Pathol., 2013, 44, 133-141.
81. Gross, D.A.; Silver, D.L. Cytosolic lipid droplets: From mechanisms of fat storage to disease. Crit. Rev. BiochemMolBiol., 2014, 49, 304-26.
82. Segatori, L. Impairment of homeostasis in lysosomal storage disorders. IUBMB Life, 2014, 66(7), 472-477.
83. Chimenti, C.; Morgante, E.; Tanzilli, G.; Mangieri, E.; Critelli, G.; Gaudio, C.; Russo, M.A.; Frustaci, A. Angina in Fabry Disease Reflects Coronary Small Vessel Disease. Circ Heart Fail., 2008, 1, 161-169.
84. Santos, B.L.; de Souza, C.F.; Schuler-Faccini, L.; Refosco, L.; Epifanio, M.; Nalin, T.; Goncalves, S.M.; Schwartz, I.V. Glycogen storage disease type I: clinical and laboratory profile. J. Pediatr. (Rio J), 2014, 90(6), 572-579.
85. Pifl, C.; Rajput, A.; Reither, H.; Blesa, J.; Cavada, C.; Obeso, J.A.; Rajput, A.H. and Hornykiewicz, O. Is Parkinson's disease a vesicular dopamine storage disorder? Evidence from a study in isolated synaptic vesicles of human and nonhuman primate striatum. J. Neurosci., 2014, 34, 8210-8.
86. Platt, F.M. Sphingolipid lysosomal storage disorders. Nature, 2014, 510, 68-75.
87. Matrone, C.; Djelloul, M.; Taglialatela, G.; Perrone, L. Inflammatory risk factors and pathologies promoting Alzheimer`s disease progression: is RAGE the key? Histol. Histopathol., 2015, 30(2), 125-139.
88. Brundin, P.; Melki, R.; Kopito, R. Prion-like transmission of protein aggregates in neurodegenerative diseases. Nat. Rev. Mol. Cell. Biol., 2010, 11, 301-7.
89. Maeda, A.; Tamura, K.; Wakui, H.; Ohsawa, M.; Azushima, K.; Uneda, K.; Kanaoka, T.; Kobayashi, R.; Ohki, K.; Matsuda, M.; Tsurumi-Ikeya, Y.; Yamashita, A.; Tokita, Y. and Umemura, S. Effects of the Angiotensin receptor blocker olmesartan on adipocyte hypertrophy and function in mice with metabolic disorders. Biomed. Res. Int., 2014, 2014, 946492.
90. Chung, S.; Cuffe, H.; Marshall, S.M.; McDaniel, A.L.; Ha, J.H.; Kavanagh, K.; Hong, C.; Tontonoz, P.; Temel, R.E.; Parks, J.S. Dietary Cholesterol Promotes Adipocyte Hypertrophy and Adipose Tissue Inflammation in Visceral, but Not in Subcutaneous, Fat in Monkeys. Arterioscler. Thromb. Vasc. Biol., 2010, 34(9), 1880-1887.
91. Hollak, C.E.; Wijburg, F.A. Treatment of lysosomal storage disorders: successes and challenges. J. Inherit. Metab. Dis., 2014, 37, 587-98.
92. Adir, Y.; Harari, S. Pulmonary hypertension associated with chronic obstructive lung disease and idiopathic pulmonary fibrosis. Curr. Opin. Pulm. Med., 2014, 20(5), 414-420.
93. Corridoni, D.; Arseneau, K.O.; Cominelli, F. Inflammatory bowel disease. Immunol. Lett., 2014, 161(2), 231-235.
94. Neubauer, J.A.; Sunderram, J. Heme oxygenase-1 and chronic hypoxia. Respir. Physiol. Neurobiol., 2012, 184, 178-85.
95. Brieger, K.; Schiavone, S.; Miller, F.J., Jr.; Krause, K.H. Reactive oxygen species: from health to disease. Swiss Med. Wkly, 2012, 142, w13659.
96. Siomek, A. NF-κB signaling pathway and free radical impact. Acta. Biochim. Pol., 2012, 59, 323-331.
97. Ponugoti, B.; Dong, G.; Graves, D.T. Role of forkhead transcription factors in diabetes-induced oxidative stress. Exp. Diabetes Res., 2012, 2012, 939751.
98. Spiro, S. Nitrous oxide production and consumption: regulation of gene expression by gas-sensitive transcription factors. Philos. Trans. R. Soc. Lond. B. BiolSci., 2012, 367, 1213-1225.
99. Brunet, A.; Berger, S.L. Epigenetics of aging and aging-related disease. J. Gerontol. A. Biol. Sci. Med. Sci., 2014, 69, S17-S20.
100. Kolovou, G.D.; Kolovou, V.; Mavrogeni, S. We Are Ageing. Biomed. Res. Int., 2014, 2014, 808307.
101. Joyner, M.J. Buying into healthy blood vessels: exercise and aging. J. Appl. Physiol., 2014, 117(5), 421-422.
102. Semenza, G.L. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends PharmacolSci., 2012, 33, 207-214.
103. Xia, Y.; Choi, H.K.; Lee, K. Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors. Eur. J. Med. Chem., 2012, 49, 24-40.
104. Jiang, B.H.; Jiang, G.; Zheng, J.Z.; Lu, Z.; Hunter, T.; Vogt, P.K. Phosphatidylinositol 3-kinase signaling controls levels of hypoxiainducible factor 1. Cell. Growth Differ., 2001, 12, 363-369.
105. Majumder, P.K.; Febbo, P.G.; Bikoff, R.; Berger, R.; Xue, Q.; McMahon, L.M.; Manola, J.; Brugarolas, J.; McDonnell, T.J.; Golub, T.R.; Loda, M.; Lane, H.A.; Sellers, W.R. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat. Med., 2004, 10, 594-601.
106. Mabjeesh, N.J.; Escuin, D.; LaVallee, T.M.; Pribluda, V.S.; Swartz, G.M.; Johnson, M.S.; Willard, M.T.; Zhong, H.; Simons, J.W.; Giannakakou, P. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell, 2003, 3, 363-375
107. Yoon, H.; Shin, S.H.; Shin, D.H.; Chun, Y.S.; Park, J.W. Differential roles of Sirt1 inHIF-1α and HIF-2α mediated hypoxic responses. Biochem. Biophys. Res. Commun., 2014, 444, 36-43.
108. Seo, K.S.; Park, J.H.; Heo, J.Y.; Jing, K.; Han, J.; Min, K.N.; Kim, C.; Koh, G.Y.; Lim, K.; Kang, G.Y.; Uee Lee, J.; Yim, Y.H.; Shong, M.; Kwak, T.H.; Kweon, G.R. SIRT2 regulates tumour hypoxia response by promoting HIF-1α hydroxylation. Oncogene, 2015, 34(11), 1354-1362.
109. Haigis, M.C.; Deng, C.X.; Finley, L.W.; Kim, H.S.; Gius, D. SIRT3 is a mitochondrial tumor suppressor: a scientific tale that connects aberrant cellular ROS, the Warburg effect, and carcinogenesis. Cancer Res, 2012, 72, 2468-2472.
110. Pellegrini, L.; Pucci, B.; Villanova, L.; Marino, M.L.; Marfe, G.; Sansone, L.; Vernucci, E.; Bellizzi, D.; Reali, V.; Fini, M.; Russo, M.A.; Tafani, M. SIRT3 protects from hypoxia and staurosporinemediated cell death by maintaining mitochondrial membrane potential and intracellular pH. Cell. Death. Differ., 2012, 19, 1815-1825.
111. Choi, H.; Chun, Y.S.; Kim, S.W.; Kim, M.S.; Park, J.W. Curcumin inhibits hypoxia inducible factor-1 by degrading aryl hydrocarbon receptor nuclear translocator: a mechanism of tumor growth inhibition. Mol. Pharmacol., 2006, 70, 1664-1671.
112. Dat, N.T.; Jin, X.; Lee, K.; Hong, Y.S.; Kim, Y.H.; Lee, J.J. Hypoxia-inducible factor-1 inhibitory benzofurans and chalconederived diels-alder adducts from Morus species. J. Nat. Prod., 2009, 72, 39-43.
113. Park, S.Y.; Jeong, K.J.; Lee, J.; Yoon, D.S.; Choi, W.S.; Kim, Y.K.; Han, J.W.; Kim, Y.M.; Kim , B.K.; Lee, H.Y. Hypoxia enhances LPA-induced HIF-1alpha and VEGF expression: their inhibition by resveratrol. Cancer Lett., 2007, 258, 63-69.
114. Liu, Y.; Veena, C.K.; Morgan, J.B.; Mohammed, K.A.; Jekabsons, M.B.; Nagle, D.G.; Zhou, Y.D. Methylalpinumisoflavone inhibits hypoxia-inducible factor-1 (HIF-1) activation by simultaneously targeting multiple pathways. J. Biol. Chem., 2009, 284, 5859-5868.
115. Dat, N.T.; Jin, X.; Lee, J.H.; Lee, D.; Hong, Y.S.; Lee, K.; Kim, Y.H.; Lee, J.J. Abietanediterpenes from Salvia miltiorrhiza inhibit the activation of hypoxia-inducible factor-1. J. Nat. Prod., 2007, 70, 1093-1097.
116. Lee, K.; Zhang, H.; Qian, D.Z.; Rey, S.; Liu, J.O. and Semenza, G.L. Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization. Proc. Natl. Acad. Sci. USA, 2009, 106, 17910-17915.
117. Tanaka, T.; Yamaguchi, J.; Shoji, K.; Nangaku, M. Anthracycline Inhibits Recruitment of Hypoxia-inducible Transcription Factors and Suppresses Tumor Cell Migration and Cardiac Angiogenic Response in the Host. J. Biol. Chem., 2012, 287, 34866-34882.
118. Befani, C.D.; Vlachostergios, P.J.; Hatzidaki, E.; Patrikidou, A.; Bonanou, S.; Simos, G.; Papandreou, C.N.; Liakos, P. Bortezomib represses HIF-1α protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells. J. Mol. Med .(Berl), 2012, 90, 45-54.
119. Kung, A.L.; Zabludoff, S.D.; France, D.S.; Freedman, S.J.; Tanner, E.A.; Vieira, A.; Cornell-Kennon, S.; Lee, J.; Wang, B.; Wang, J.; Memmert, K.; Naegeli, H.U.; Petersen, F.; Eck, M.J.; Bair, K.W.; Wood, A.W.; Livingston, D.M. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell, 2004, 6, 33-43.
120. Yang, D.; Wei, F.; Tewary, P.; Howard, O.M.; Oppenheim, J.J. Alarmin-induced cell migration. Eur. J. Immunol., 2013, 43, 1412-1418.
121. Alexiou, P.; Chatzopoulou, M.; Pegklidou, K.; Demopoulos, V.J. RAGE: a multi-ligand receptor unveiling novel insights in health and disease. Curr Med Chem, 2010, 17, 2232-2252.
122. Yamagishi, S.; Nakamura, K.; Matsui, T.; Ueda, S.; Fukami, K.; Okuda, S. Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications. Expert Opin Investig Drugs, 2008, 17, 983-996.
123. Yan, S.F.; Ramasamy, R.; Schmidt, A.M. Soluble RAGE: therapy and biomarker in unraveling the RAGE axis in chronic disease and aging. Biochem Pharmacol, 2010, 79, 1379-1386.
124. Puddu, A.; Mach, F.; Nencioni, A.; Viviani, G.L.; Montecucco, F. An emerging role of glucagon-like peptide-1 in preventing advanced-glycation-end-product-mediated damages in diabetes. Mediators Inflamm., 2013, 2013, 591056.
125. Bahner, J.D.; Bordeaux, J.S. Non-melanoma skin cancers: photodynamic therapy, cryotherapy, 5-fluorouracil, imiquimod, diclofenac, or what? Facts and controversies. Clin. Dermatol., 2013, 31, 792-798.
126. Hennessy, E.J.; Parker, A.E.; O'Neill, L.A. Targeting Toll-like receptors: emerging therapeutics? Nat Rev Drug Discov, 9, 293-307.
127. O'Neill, L.A.; Bryant, C.E. and Doyle, S.L. Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer. Pharmacol. Rev., 2009, 61, 177-197.
128. Krieg, A.M. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer.Oncogene, 2008, 27, 161-167.
129. Kochling, J.; Prada, J.; Bahrami, M.; Stripecke, R.; Seeger, K.; Henze, G.; Wittig, B.; Schmidt, M. Anti-tumor effect of DNAbased vaccination and dSLIM immunomodulatory molecules in mice with Ph+ acute lymphoblastic leukaemia. Vaccine, 2008, 26, 4669-4675.
130. D'Agostini, C.; Pica, F.; Febbraro, G.; Grelli, S.; Chiavaroli, C.; Garaci, E. Antitumour effect of OM-174 and cyclophosphamide on murine B16 melanoma in different experimental conditions. IntImmunopharmacol, 2005, 5, 1205-1212.
131. Murata, M. Activation of Toll-like receptor 2 by a novel preparation of cell wall skeleton from Mycobacterium bovis BCG Tokyo (SMP-105) sufficiently enhances immune responses against tumors. Cancer Sci., 2008, 99, 1435-1440.
132. Mark, K.E.; Corey, L.; Meng, T.C.; Magaret, A.S.; Huang, M.L.; Selke, S.; Slade, H.B.; Tyring, S.K.; Warren, T.; Sacks, S.L.; Leone, P.; Bergland, V.A.; Wald, A. Topical resiquimod 0.01% gel decreases herpes simplex virus type 2 genital shedding: a randomized, controlled trial. J. Infect. Dis., 2007, 195, 1324-1331.
133. Kronenberger, B.; Zeuzem, S. New developments in HCV therapy. J. Viral. Hepat., 2012, 19(Suppl 1), 48-51.
134. Sun, S.; Rao, N.L.; Venable, J.; Thurmond, R.; Karlsson, L. TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders. Inflamm. Allergy Drug Targets, 2007, 6, 223-235.
135. Parkinson, T. The future of toll-like receptor therapeutics. Curr. Opin. Mol. Ther., 2008, 10, 21-31.
136. Ungaro, R.; Fukata, M.; Hsu, D.; Hernandez, Y.; Breglio, K.; Chen, A.; Xu, R.; Sotolongo, J.; Espana, C.; Zaias, J.; Elson, G.; Mayer, L.; Kosco-Vilbois, M.; Abreu, M.T. A novel Toll-like receptor 4 antagonist antibody ameliorates inflammation but impairs mucosal healing in murine colitis. Am. J. Physiol. Gastrointest. Liver Physiol., 2009, 296, G1167-G1179.
137. Lamkanfi, M. Emerging inflammasome effector mechanisms. Nat. Rev. Immunol., 2011, 11, 213-220.
138. Moll, M.; Kuemmerle-Deschner, J.B. Inflammasome and cytokine blocking strategies in autoinflammatory disorders. Clin. Immunol, 2013, 147, 242-275.
139. Hedrich, C.M.; Bruck, N.; Fiebig, B.; Gahr, M. Anakinra: a safe and effective first-line treatment in systemic onset juvenile idiopathic arthritis (SoJIA). Rheumatol. Int., 2012, 32, 3525-30.
140. Zhao, J.; Wang, H.; Dai, C.; Wang, H.; Zhang, H.; Huang, Y.; Wang, S.; Gaskin, F.; Yang, N.; Fu, S.M. P2X7 blockade attenuates murine lupus nephritis by inhibiting activation of the NLRP3/ ASC/caspase 1 pathway. Arthritis Rheum, 2013, 65, 3176-3185.
141. Juliana, C.; Fernandes-Alnemri, T.; Wu, J.; Datta, P.; Solorzano, L.; Yu, J.W.; Meng, R.; Quong, A.A.; Latz, E.; Scott, C.P.; Alnemri, E.S. Anti-inflammatory compounds parthenolide and Bay 11-7082 are direct inhibitors of the inflammasome. J. Biol. Chem., 2010, 285, 9792-9802.
142. Gupta, S.C.; Sundaram, C.; Reuter, S.; Aggarwal, B.B. Inhibiting NF-κB activation by small molecules as a therapeutic strategy. Biochim Biophys Acta, 2010, 1799, 775-787.
143. Karin, M.; Yamamoto, Y.; Wang, Q.M. The IKK NF-kappa B system: a treasure trove for drug development. Nat. Rev. Drug Discov., 2004, 3, 17-26
144. Lubbad, A.; Oriowo, M.A.; Khan, I. Curcumin attenuates inflammation through inhibition of TLR-4 receptor in experimental colitis. Mol Cell Biochem, 2009, 322, 127-135.
145. Kast, R.E. Aspirin, TNF-alpha, NFkB, and survival in multiple myeloma: the importance of measuring TNF-alpha. Inflammopharmacology, 2006, 14, 256-9.
146. Sreenivasan, Y., Sarkar, A.; Manna, S.K. Mechanism of cytosine arabinoside-mediated apoptosis: role of Rel A (p65) dephosphorylation. Oncogene, 2003, 22, 4356-69.
147. Kale, A.J.; Moore, B.S. (2012). Molecular Mechanisms of Acquired Proteasome Inhibitor Resistance. J. Med. Chem., 2012, 55, 10317-10327.
148. Wilczynski, J.; Duechler, M.; Czyz, M. Targeting NF-κB and HIF-1 pathways for the treatment of cancer: part I. Arch Immunol Ther Exp (Warsz), 2011, 59, 289-299.
149. Gray, S.G.; Teh, B.T. Histone acetylation/deacetylation and cancer: an "open" and "shut" case? Curr. Mol. Med., 2001, 1, 401-429.
150. Kozakai, N.; Kikuchi, E.; Hasegawa, M.; Suzuki, E.; Ide, H.; Miyajima, A.; Horiguchi, Y.; Nakashima, J.; Umezawa, K.; Shigematsu, N.; Oya, M. Enhancement of radiosensitivity by a unique novel NF-κB inhibitor, DHMEQ, in prostate cancer. Br. J. Cancer, 2012, 107, 652-657.